# A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

> **NCT02127710** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 111 (actual)

## Conditions studied

- Papillary Renal Cell Cancer

## Interventions

- **DRUG:** AZD6094

## Key facts

- **NCT ID:** NCT02127710
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-30
- **Primary completion:** 2016-04-14
- **Final completion:** 2020-04-20
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2021-04-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02127710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02127710, "A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02127710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*